Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population
Abstract Performance of three automated commercial serological IgG-based assays was investigated for assessing SARS-CoV-2 “ever” (past or current) infection in a population-based sample in a high exposure setting. PCR and serological testing was performed on 394 individuals. SARS-CoV-2-IgG seropreva...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/00d05365c24d417eba4890d7150a2789 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:00d05365c24d417eba4890d7150a2789 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:00d05365c24d417eba4890d7150a27892021-12-02T17:51:13ZAnalytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population10.1038/s41598-021-91235-x2045-2322https://doaj.org/article/00d05365c24d417eba4890d7150a27892021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-91235-xhttps://doaj.org/toc/2045-2322Abstract Performance of three automated commercial serological IgG-based assays was investigated for assessing SARS-CoV-2 “ever” (past or current) infection in a population-based sample in a high exposure setting. PCR and serological testing was performed on 394 individuals. SARS-CoV-2-IgG seroprevalence was 42.9% (95% CI 38.1–47.8%), 40.6% (95% CI 35.9–45.5%), and 42.4% (95% CI 37.6–47.3%) using the CL-900i, VidasIII, and Elecsys assays, respectively. Between the three assays, overall, positive, and negative percent agreements ranged between 93.2–95.7%, 89.3–92.8%, and 93.8–97.8%, respectively; Cohen’s kappa statistic ranged from 0.86 to 0.91; and 35 specimens (8.9%) showed discordant results. Among all individuals, 12.5% (95% CI 9.6–16.1%) had current infection, as assessed by PCR. Of these, only 34.7% (95% CI 22.9–48.7%) were seropositive by at least one assay. A total of 216 individuals (54.8%; 95% CI 49.9–59.7%) had evidence of ever infection using antibody testing and/or PCR during or prior to this study. Of these, only 78.2%, 74.1%, and 77.3% were seropositive in the CL-900i, VidasIII, and Elecsys assays, respectively. All three assays had comparable performance and excellent agreement, but missed at least 20% of individuals with past or current infection. Commercial antibody assays can substantially underestimate ever infection, more so when infection rates are high.Gheyath K. NasrallahSoha R. DarghamFarah ShurrabDuaa W. Al-SadeqHadeel Al-JighefeeHiam ChemaitellyZaina Al KanaaniAbdullatif Al KhalEinas Al KuwariPeter CoyleAndrew JeremijenkoAnvar Hassan KaleeckalAli Nizar LatifRiyazuddin Mohammad ShaikHanan F. Abdul RahimHadi M. YassineMohamed G. Al KuwariHamda QotbaHamad Eid Al RomaihiPatrick TangRoberto BertolliniMohamed H. Al-ThaniAsmaa A. AlthaniLaith J. Abu-RaddadNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Gheyath K. Nasrallah Soha R. Dargham Farah Shurrab Duaa W. Al-Sadeq Hadeel Al-Jighefee Hiam Chemaitelly Zaina Al Kanaani Abdullatif Al Khal Einas Al Kuwari Peter Coyle Andrew Jeremijenko Anvar Hassan Kaleeckal Ali Nizar Latif Riyazuddin Mohammad Shaik Hanan F. Abdul Rahim Hadi M. Yassine Mohamed G. Al Kuwari Hamda Qotba Hamad Eid Al Romaihi Patrick Tang Roberto Bertollini Mohamed H. Al-Thani Asmaa A. Althani Laith J. Abu-Raddad Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population |
| description |
Abstract Performance of three automated commercial serological IgG-based assays was investigated for assessing SARS-CoV-2 “ever” (past or current) infection in a population-based sample in a high exposure setting. PCR and serological testing was performed on 394 individuals. SARS-CoV-2-IgG seroprevalence was 42.9% (95% CI 38.1–47.8%), 40.6% (95% CI 35.9–45.5%), and 42.4% (95% CI 37.6–47.3%) using the CL-900i, VidasIII, and Elecsys assays, respectively. Between the three assays, overall, positive, and negative percent agreements ranged between 93.2–95.7%, 89.3–92.8%, and 93.8–97.8%, respectively; Cohen’s kappa statistic ranged from 0.86 to 0.91; and 35 specimens (8.9%) showed discordant results. Among all individuals, 12.5% (95% CI 9.6–16.1%) had current infection, as assessed by PCR. Of these, only 34.7% (95% CI 22.9–48.7%) were seropositive by at least one assay. A total of 216 individuals (54.8%; 95% CI 49.9–59.7%) had evidence of ever infection using antibody testing and/or PCR during or prior to this study. Of these, only 78.2%, 74.1%, and 77.3% were seropositive in the CL-900i, VidasIII, and Elecsys assays, respectively. All three assays had comparable performance and excellent agreement, but missed at least 20% of individuals with past or current infection. Commercial antibody assays can substantially underestimate ever infection, more so when infection rates are high. |
| format |
article |
| author |
Gheyath K. Nasrallah Soha R. Dargham Farah Shurrab Duaa W. Al-Sadeq Hadeel Al-Jighefee Hiam Chemaitelly Zaina Al Kanaani Abdullatif Al Khal Einas Al Kuwari Peter Coyle Andrew Jeremijenko Anvar Hassan Kaleeckal Ali Nizar Latif Riyazuddin Mohammad Shaik Hanan F. Abdul Rahim Hadi M. Yassine Mohamed G. Al Kuwari Hamda Qotba Hamad Eid Al Romaihi Patrick Tang Roberto Bertollini Mohamed H. Al-Thani Asmaa A. Althani Laith J. Abu-Raddad |
| author_facet |
Gheyath K. Nasrallah Soha R. Dargham Farah Shurrab Duaa W. Al-Sadeq Hadeel Al-Jighefee Hiam Chemaitelly Zaina Al Kanaani Abdullatif Al Khal Einas Al Kuwari Peter Coyle Andrew Jeremijenko Anvar Hassan Kaleeckal Ali Nizar Latif Riyazuddin Mohammad Shaik Hanan F. Abdul Rahim Hadi M. Yassine Mohamed G. Al Kuwari Hamda Qotba Hamad Eid Al Romaihi Patrick Tang Roberto Bertollini Mohamed H. Al-Thani Asmaa A. Althani Laith J. Abu-Raddad |
| author_sort |
Gheyath K. Nasrallah |
| title |
Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population |
| title_short |
Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population |
| title_full |
Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population |
| title_fullStr |
Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population |
| title_full_unstemmed |
Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population |
| title_sort |
analytic comparison between three high-throughput commercial sars-cov-2 antibody assays reveals minor discrepancies in a high-incidence population |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/00d05365c24d417eba4890d7150a2789 |
| work_keys_str_mv |
AT gheyathknasrallah analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT sohardargham analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT farahshurrab analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT duaawalsadeq analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT hadeelaljighefee analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT hiamchemaitelly analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT zainaalkanaani analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT abdullatifalkhal analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT einasalkuwari analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT petercoyle analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT andrewjeremijenko analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT anvarhassankaleeckal analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT alinizarlatif analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT riyazuddinmohammadshaik analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT hananfabdulrahim analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT hadimyassine analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT mohamedgalkuwari analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT hamdaqotba analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT hamadeidalromaihi analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT patricktang analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT robertobertollini analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT mohamedhalthani analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT asmaaaalthani analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation AT laithjaburaddad analyticcomparisonbetweenthreehighthroughputcommercialsarscov2antibodyassaysrevealsminordiscrepanciesinahighincidencepopulation |
| _version_ |
1718379267066167296 |